Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Next Previous
Trial Profile

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Doxorubicin; Paclitaxel; Tamoxifen
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Alliance

Most Recent Events

  • 06 Jun 2023 Results of pooled analysis from NCT00045032, ISRCTN76560285, NCT00005970, NCT00004067, NCT00054587, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 13 Apr 2022 Results of pooled analysis of NCT00005970, NCT00024102, evaluating Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival, presented at the 113th Annual Meeting of the American Association for Cancer Research
  • 13 Apr 2022 Results of an analysis assessed the integrated pathological quantification and genomic data to assess functional tertiary lymphoid structure presented at the 113th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top